Expanded Access Use of Tucatinib for HER2+ Metastatic Breast Cancer

NCT03424473CI-TRIAL-00043604no longer availableClinicalTrials.gov clinicaltrialsPublishedExplore in graph →

Summary

Brief summary (as posted)

Physicians interested in requesting a single patient IND should contact Seattle Genetics' Medical Information (medinfo@seagen.com).

Conditions

Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.

Data not yet available

No condition recorded.

Interventions

Intervention	Type	Mapped drug	Match
Tucatinib	Drug	Tucatinib	ALIAS

Eligibility

Show eligibility criteria text

Inclusion Criteria:

\-

Exclusion Criteria:

\-

References

Data not yet available

No reference posted for this study.

Registry

Start: —
Primary completion: —
Completion: —
First posted: Feb 7, 2018
Last update posted: Feb 25, 2020
Lead sponsor: Seagen Inc. INDUSTRY
Keywords: tucatinib, Breast Cancer, ARRY-380, ONT-380, HER2 Positive Breast Carcinoma, HER2 Positive Locally Advanced Breast Cancer, HER-2 Positive Breast Cancer, HER-2 Positive Locally Advanced Breast Cancer, Recurrent Breast Carcinoma, Stage IV Breast Cancer, Metastatic Breast Cancer, Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain, Brain Metastases in Breast Cancer, Breast Neoplasms, Neoplasms by Site, Neoplasms, Breast Diseases

Data updated 22 days agoSource updated Feb 25, 2020source: clinicaltrials

Locations

No location posted.

Trial listing is informational. Eligibility is decided by the study team; contact information is on ClinicalTrials.gov.